Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhPro-uk thrombolysis followed by PCI at different times in STEMI
ChiCTR2100049542Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Aug 2021
- Modality
- Metabolic Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of recombinant human prourokinase in myocardial infarction (MI) (3 arms), sponsored by The First Affiliated Hospital of USTC. Primary endpoints: Post-PCI myocardial perfusion and no-reflow, In-hospital major bleeding, mortality, and recurrent ischemia and 2 more. Started Aug 2021; status: recruiting.
02
Drugs
recombinant human prourokinase
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2100049542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049542.